Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation

European Journal of Clinical Investigation

Volumn 47, Issue 2, 2017, Pages 149-157

  Wernly, Bernhard ^a   Lichtenauer, Michael ^a   Jirak, Peter ^a   Eder, Sarah ^a   Reiter, Christian ^b   Kammler, Jürgen ^b   Kypta, Alexander ^b   Jung, Christian ^c   Franz, Marcus ^d   Hoppe, Uta C ^a   Landmesser, Ulf ^e,f   Figulla, Hans Reiner ^d   Lauten, Alexander ^e,f  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Aortic stenosis; biomarker; outcome; ST2; transcatheter aortic valve implantation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

AGED; AORTA VALVE PROSTHESIS; ARTICLE; EUROSCORE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSCATHETER AORTIC VALVE IMPLANTATION DEVICE; TREATMENT OUTCOME; VERY ELDERLY; YOUDEN INDEX; AORTIC VALVE STENOSIS; BLOOD; COHORT ANALYSIS; EVALUATION STUDY; HEART STROKE VOLUME; METABOLISM; PHYSIOLOGY;

AORTIC VALVE STENOSIS; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; STROKE VOLUME; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 85010767473     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12719     Document Type: Article

References (34)

1. Noble S, Frangos E, Samaras N, Ellenberger C, Frangos C, Cikirikcioglu M et al. Transcatheter aortic valve implantation in nonagenarians: effective and safe. Eur J Intern Med 2013;24:750–5.
2. Horne A Jr, Reineck EA, Hasan RK, Resar JR, Chacko M. Transcatheter aortic valve replacement: historical perspectives, current evidence, and future directions. Am Heart J 2014;168:414–23.
3. Panayiotides IM, Nikolaides E. Transcatheter aortic valve implantation (TAVI): is it time for this intervention to be applied in a lower risk population? Clin Med Insights Cardiol 2014;8:93–102.
4. Gooley R, Cameron JD, Meredith IT. Transcatheter aortic valve implantation – yesterday, today and tomorrow. Heart Lung Circ 2015;24:1149–61.
5. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1–44.
6. Moreno R, Calvo L, Salinas P, Dobarro D, Santiago JV, Sanchez-Recalde A et al. Causes of peri-operative mortality after transcatheter aortic valve implantation: a pooled analysis of 12 studies and 1223 patients. J Invasive Cardiol 2011;23:180–4.
7. Arangalage D, Cimadevilla C, Alkhoder S, Chiampan A, Himbert D, Brochet E et al. Agreement between the new EuroSCORE II, the Logistic EuroSCORE and the Society of Thoracic Surgeons score: implications for transcatheter aortic valve implantation. Arch Cardiovasc Dis 2014;107:353–60.
8. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9–13.
9. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816–22; discussion 22–3.
10. Gogbashian A, Sedrakyan A, Treasure T. EuroSCORE: a systematic review of international performance. Eur J Cardiothorac Surg 2004;25:695–700.
11. Schenk S, Fritzsche D, Atoui R, Koertke H, Koerfer R, Eitz T. EuroSCORE-predicted mortality and surgical judgment for interventional aortic valve replacement. J Heart Valve Dis 2010;19:5–15.
12. Hinterbuchner L, Strohmer B, Hammerer M, Prinz E, Hoppe UC, Schernthaner C. Frailty scoring in transcatheter aortic valve replacement patients. Eur J Cardiovasc Nurs 2016;15:384–97.
13. Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart 2015;101:1382–8.
14. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961–6.
15. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721–6.
16. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015;443:57–70.
17. Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, Hantusch B et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 2013;37:658–65.
18. Bayes-Genis A, Zhang Y, Ky B. ST2 and patient prognosis in chronic heart failure. Am J Cardiol 2015;115:64B–9B.
19. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol 2015;115:70B–5B.
20. Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol 2015;115:48B–58B.
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.
22. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 2012;14:268–77.
23. Lancellotti P, Dulgheru R, Magne J, Henri C, Servais L, Bouznad N et al. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. PLoS One 2015;10:e0138940.
24. Frioes F, Lourenco P, Laszczynska O, Almeida PB, Guimaraes JT, Januzzi JL et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 2015;104:491–9.
25. Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013;19:821–8.
26. Piper S, deCourcey J, Sherwood R, Amin-Youssef G, McDonagh T. Biologic variability of soluble ST2 in patients with stable chronic heart failure and implications for monitoring. Am J Cardiol 2016;118:95–8.
27. Dworakowski R, Wendler O, Bhan A, Smith L, Pearson P, Alcock E et al. Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction. Heart 2012;98:1641–6.
28. Guo X, Ma X, Yang Q, Xu J, Huang L, Jia J et al. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). Eur J Med Chem 2014;81:89–94.
29. Tung YC, Chang CH, Chen YC, Chu PH. Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS One 2015;10:e0125282.
30. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607–13.
31. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research. J Am Coll Cardiol 2008;52:1466–7.
32. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54:752–6.
33. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41–5.
34. Silaschi M, Conradi L, Seiffert M, Schnabel R, Schon G, Blankenberg S et al. Predicting risk in transcatheter aortic valve implantation: comparative analysis of EuroSCORE II and established risk stratification tools. Thorac Cardiovasc Surg 2015;63:472–8.